Generalized Chorea and JAK2V617F Mutation-Positive Myeloproliferative Disorders. [PDF]
An 86-year-old right-handed man presented with 1 month of involuntary movements. He had involuntary facial grimacing, tongue chewing, grunting, slurred speech, shoulder shrugging, and leg movements. He was not able to suppress the movements, felt no urge
Betté S, Moore H.
europepmc +5 more sources
JAK2V617F Mutation in Patient with Splanchnic Vein Thrombosis. [PDF]
Splanchnic vein thrombosis is an uncommon life-threatening form of venous thrombosis. It is one the common complication among MPN's. In the western studies the prevalence of JAK2V617F mutation among SVT patient is high and ranges from 7 to 59%. The frequency of this mutation among Indian SVT patients is heterogenous. This was a prospective case control
Kumar N +8 more
europepmc +5 more sources
Exacerbation of thromboinflammation by JAK2V617F mutation worsens the prognosis of cerebral venous sinus thrombosis. [PDF]
Key Points • JAK2V617F mutation contributes to hemorrhagic lesions and to mortality in an experimental model of cerebral venous thrombosis.• JAK2V617F mutation exacerbates thromboinflammatory response during cerebral venous thrombosis.
Bourrienne MC +21 more
europepmc +2 more sources
Interleukin-1β, JAK2V617F mutation and inflammation in MPNs. [PDF]
Long before the discovery of the ...
Hermouet S, Hasselbalch HC.
europepmc +2 more sources
The JAK2V617F mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden [PDF]
Alleviating symptom burden in patients with myeloproliferative neoplasms (MPNs) is imperative to achieving optimal management. Research remains to elucidate the relationship between the JAK2V617F (Janus kinase 2) mutation present in many MPN patients ...
Lai Yee Orbell +7 more
doaj +2 more sources
JAK2V617F Mutation in Ischemic Stroke: Bridging Hematology and Stroke Neurology [PDF]
Recent evidence suggests the JAK2V617F mutation may confer an elevated risk of ischemic stroke, likely mediated by systemic inflammation, abnormal cell activation, and endothelial dysfunction.
Marie H. Kristiansen +7 more
doaj +2 more sources
Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm. [PDF]
Rational The myeloproliferative neoplasms (MPNs) are clonal hematological malignancies characterized by hematopoietic stem cell expansion and overproduction of mature blood cells.
Castiglione M +9 more
europepmc +2 more sources
SRSF2 mutations are found in association with JAK2V617F in myeloproliferative neoplasms (MPN), most frequently in myelofibrosis (MF). However, the contribution of SRSF2 mutation in JAK2V617F-driven MPN remains elusive.
Yue Yang +4 more
doaj +2 more sources
Thromboinflammation in ischemic cerebrovascular patients with the JAK2V617F mutation. [PDF]
BACKGROUND The JAK2V617F mutation is a driver of Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) and is also implicated in cardiovascular diseases.
M. H. Kristiansen +9 more
semanticscholar +4 more sources
Background: It is still a matter of debate regarding the association of JAK2V617F mutation with thrombosis in BCR-ABL negative CMPN patients. The role of JAK2V617F mutation in increasing the thrombotic risk in CMPNs is yet unequivocal.
Kanwaljeet Singh +4 more
doaj +2 more sources

